CENTOGENE to Participate in Upcoming Conferences in November
November 10 2022 - 6:30AM
Centogene N.V. (Nasdaq: CNTG), the essential life science partner
for data-driven answers in rare and neurodegenerative diseases,
today announced its conference schedule for November 2022. The
Company’s Pharma and CRO business development team and Diagnostics
sales team will be attending events in the U.S. and Spain.
CENTOGENE invites attendees to schedule one-on-one meetings.
Please see additional details below:
World Orphan Drug Congress (WODC) Europe
2022 |
|
|
Dates: |
November 14-17, 2022 |
|
|
Location: |
Melia Sitges Hotel, Barcelona, Spain |
|
|
For information about WODC Europe 2022, please refer to the event
website
(https://www.terrapinn.com/conference/world-orphan-drug-congress/index.stm). CENTOGENE’s
Pharma and CRO business development team can be contacted directly
at BD@centogene.com to set one-on-one meetings. |
National Society of Genetic Counselors
(NSGC) Annual Conference 2022 |
|
|
Dates: |
November 16-20, 2022 |
|
|
Location: |
Music City Center, Nashville, TN, U.S. |
|
|
Booth: |
#715 |
|
|
To learn more about the NSGC Annual Conference, please visit the
event website (https://www.nsgc.org/conference). To set up a
one-on-one meeting with the CENTOGENE team, contact
renee.hoch@centogene.com. |
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with nearly
700,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 260 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target & drug screening, clinical
development, market access and expansion, as well as offering
CENTOGENE Biodatabank Licenses and Insight Reports to enable a
world healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative economic and geopolitical conditions and instability and
volatility in the worldwide financial markets, possible changes in
current and proposed legislation, regulations and governmental
policies, pressures from increasing competition and consolidation
in our industry, the expense and uncertainty of regulatory
approval, including from the U.S. Food and Drug Administration, our
reliance on third parties and collaboration partners, including our
ability to manage growth and enter into new client relationships,
our dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our
reliance on intellectual property protection, fluctuations of our
operating results due to the effect of exchange rates, our ability
to streamline cash usage, our requirement for additional financing,
or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on March 31, 2022,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Media Contact:
CENTOGENE Ben Legg Corporate
Communications Press@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Apr 2023 to Apr 2024